share_log

瑞银:维持药明康德(02359)“中性”评级 目标价降至40.1港元

UBS: Maintaining the “neutral” rating of Pharmacovigilance (02359), the target price was reduced to HK$40.1

Zhitong Finance ·  Apr 30 11:26

At present, Yao Ming Kangde's management remains unchanged at the target of revenue of 38.3 billion yuan to 40.5 billion yuan in 2024.

The Zhitong Finance App learned that UBS released a research report stating that it maintained Yao Ming Kangde (02359)'s “neutral” rating and lowered the 2024-2026 earnings forecast by 4%, 5%, and 5% to 2026 to $3.47, $3.73 and RMB 3.99, and the target price was lowered from HK$44 to HK$40.1 based on first-quarter performance.

According to the report, the company's first-quarter performance was poor, with revenue falling 11% year-on-year to 7.98 billion yuan, lower than the bank's forecast of 8.83 billion yuan and the market's general forecast of 8.41 billion yuan; net profit fell 10.4% to 1.94 billion yuan, also lower than UBS and the market forecast of 2.13 billion yuan and 2.04 billion yuan.

The bank said that excluding the impact of COVID-related revenue, Yao Ming Kangde's revenue in the first quarter fell 1.8% year on year. Among them, revenue from the US and European markets increased by 0.4% and 3.9%, while revenue from the Chinese market fell 3.3%. Management currently maintains the 2024 revenue target of 38.3 billion yuan to 40.5 billion yuan. Excluding COVID-related estimates, annual revenue will increase 2.7% to 8.6% year over year, and capital expenditure and free cash flow targets will remain unchanged.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment